June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Subthreshold micropulse laser treatment for chronic central serous chorioretinopathy with persistent subretinal fluid
Author Affiliations & Notes
  • Paula Scholz
    Department of Ophthalmology, University of Cologne, Cologne, Germany
  • Lebriz Ersoy
    Department of Ophthalmology, University of Cologne, Cologne, Germany
  • Sascha Fauser
    Department of Ophthalmology, University of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships Paula Scholz, Quantel Medical (R); Lebriz Ersoy, None; Sascha Fauser, Quantel Medical (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5681. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Paula Scholz, Lebriz Ersoy, Sascha Fauser; Subthreshold micropulse laser treatment for chronic central serous chorioretinopathy with persistent subretinal fluid. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5681.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the treatment outcome of 577nm subthreshold micropulse laser (SML) treatment for chronic central serous chorioretinopathy (CSC) with persistent subretinal fluid (SRF).

Methods: This retrospective study included 38 eyes of 33 consecutive patients who were treated with a 577nm SML (Supra Scan, Quantel Medical) for chronic CSC with persistent SRF. Patients with any prior treatment within the last 3 months were excluded. A confluent SML treatment was performed at the leakage sites detected by fluorescein and indocyanine green angiography. Examinations before and after SML treatment included best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SDOCT).

Results: 20 eyes received one SML treatment, 18 eyes 2 treatments and 8 eyes 3 treatments. Mean follow-up after the first SML treatment was 5.5 months (1-11 months). At the last follow-up, in 9 eyes (24%) the SRF had dissolved completely and in 18 eyes (47%) the SRF was reduced. Eleven eyes (29%) showed no improvement. The central retinal thickness (CRT) decreased significantly after treatment (mean CRT before SML: 393±140 µm, after SML: 289±80 µm, p< 0.01) and BCVA showed a significant increase (p<0.05). No laser scars were detected after treatment. In the subgroup of PDT therapy resistant patients (n=21) with one or more half dose PDT treatments in the past, in 3 eyes (14%) the SRF had dissolved completely and in 12 eyes (57%) the SRF was reduced. Six eyes (29%) showed no improvement. The CRT decreased significantly after treatment (mean CRT before SML: 347±125 µm, after SML: 284±73 µm, p< 0.01) and BCVA showed a significant increase (p<0.05).

Conclusions: The 577nm SML treatment is effective in the treatment of chronic CSC with persistent SRF. Even patients without improvement after PDT benefited from SML.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×